AbstrAct
Mitochondria are dynamic organelles present in virtually all human cells that are needed for a multitude of cellular functions, including energy production, control of cell apoptosis and numerous biochemical catabolic and synthetic pathways that are critical for cellular health. Primary mitochondrial disorders are a group of greater than 200 single gene defects arising from two genomes (nuclear and mitochondrial) leading to mitochondrial dysfunction, and are associated with extremely heterogeneous phenotypes. Neuromuscular features predominate, but often with multisystem involvement. Clinical suspicion of a mitochondrial disorder should prompt multipronged investigation with biochemical and molecular genetic studies. Recent wide-scale adoption of next-generation sequencing approaches has led to a rapid increase in the number of disease genes. The advances in unravelling the genetic landscape of mitochondrial diseases have not yet been matched by progress in developing effective therapies, and the mainstay of care remains supportive therapies in a multidisciplinary team setting.
MitochondriAl physiology And genetics
The mitochondrion is an ubiquitous and dynamic cellular organelle with many fundamental roles in maintaining normal cellular function. Since the mitochondrion was first described in the late 19th century by Altmann and Benda, 1 our understanding of the complexities of mitochondrial function, maintenance and replication, and the often catastrophic implications of mitochondrial dysfunction, has greatly advanced.
Mitochondria are composed of a cardiolipin-containing double membrane, with the outer mitochondrial membrane surrounding the highly convoluted inner mitochondrial membrane. The five protein multicomplexes of the respiratory chain are embedded in the inner membrane, while the mitochondrial matrix contains the enzymes of numerous associated metabolic pathways including the tricarboxylic acid (TCA) cycle, part of the urea cycle and the machinery of fatty acid beta-oxidation. Complexes I-IV of the respiratory chain/ electron transport chain use the reducing potential of NADH and FADH 2 generated by glycolysis, the TCA cycle and fatty acid oxidation to pump protons into the intermembrane space, thereby generating an electrochemical gradient which complex V dissipates to facilitate the phosphorylation of ADP to generate ATP, the fundamental 'energy currency' of the cell. In addition to energy production, control of cell apoptosis and numerous biochemical synthetic pathways are crucial mitochondrial functions that also contribute to the pathophysiology when mitochondrial function is deranged.
Mitochondrial proteins are encoded in genes held in the nuclear DNA and also in the mitochondrial DNA (mtDNA). mtDNA is a small 37-gene, ~16.5 kb DNA molecule found in multiple copies within the mitochondrial matrix. 2 Together, the nuclear and mitochondrial genomes encode more than 1500 proteins involved in mitochondrial structure and function, 3 including several nuclear genes that encode machinery important in the replication and maintenance of the mtDNA. 4 Primary mitochondrial diseases are known to be caused by mutations in more than 200 of the nuclear genes (figure 1A), inherited in Mendelian patterns (autosomal recessive, autosomal dominant or X-linked) and all the 37 mtDNA-encoded genes (figure 1B). 5 As mtDNA is only acquired from the maternal gamete (ovum) at conception, mtDNA mutations are maternally inherited, or may be sporadic de novo events.
MtDNA has a high copy number (hundreds or thousands of copies per cell) and normal and mutated mtDNA often coexist in the same cell, a phenomenon called heteroplasmy. Problems only arise if the proportion of mtDNA that is mutated exceeds a threshold. As the level of mutant mtDNA varies between individuals and between tissues in any one individual, different patients with the same mtDNA mutation can have very different symptoms
recognition of MitochondriAl diseAse
Mitochondrial disorders are thought to affect around 1:5000 of the population. 6 There is a wide heterogeneity in the clinical phenotype, with involvement of either single or multiple organ systems and the consequent clinical features (table 1). The age of presentation also varies widely, ranging from neonatal onset with fulminant lactic acidosis to relatively mild disease in old age.
Highly energetic tissues including skeletal muscle and nervous system are the most commonly affected due to their greater reliance on mitochondrial ATP synthesis. However, any organ system can be affected and one of the 'red flags' alerting clinicians to the potential for a mitochondrial disorder is the association of neurological or muscular symptoms with concurrent or subsequent multi-organ involvement. The occurrence of muscle or central nervous system disease with involvement of two or more other organ systems, or any combination of disease affecting three or more organ systems should prompt consideration of mitochondrial disease. The multitude of potential presenting review features means that mitochondrial diseases may be encountered by numerous medical specialists.
Mitochondrial diseases are also progressive, with fluctuation and deterioration expected over time, with the potential for additional organ systems to be involved as time progresses. Progressive involvement of neuromuscular systems will often present with neurological regression in the developing child, and progressive loss of skills at any age.
phenotypic syndromes
Certain clinically distinct clusters of symptoms and features are recognised as phenotypic mitochondrial syndromes. Recognition review of a mitochondrial syndrome can lead directly to a specific genetic diagnosis. It is, however, well recognised that the same genetic mutation or deletion can give rise to varied phenotypes, and conversely certain phenotypes can be caused by mutations in a range of different genes.
Leigh syndrome
Leigh and Leigh-like syndromes are infantile onset mitochondrial encephalopathies associated with bilateral symmetrical brain lesions particularly affecting the basal ganglia, thalamus and brain stem. Affected individuals usually present in the first year of life with developmental regression, respiratory abnormalities, feeding difficulties and frequently with ophthalmic involvement (nystagmus, retinal dysfunction, ophthalmoplegia). 7 8 The genetic basis of these disorders is diverse, encompassing both nuclear and mtDNA mutations involving at least 89 different genes. 9 Originally a postmortem pathological diagnosis, typical in vivo MRI patterns are now the cornerstone of diagnosis of Leigh syndrome.
Alpers syndrome
Alpers syndrome is defined by progressive neurodegeneration, refractory seizures and liver dysfunction. It is usually caused by mutations in the nuclear gene POLG which encodes the catalytic subunit of DNA polymerase gamma (polγ) which is required for the correct replication of mtDNA. 10 Dysfunction of polγ leads to progressive depletion of mtDNA with subsequent mitochondrial dysfunction. Valproate toxicity is well recognised and this should be avoided in patients with this diagnosis.
Mitochondrial recessive ataxia syndrome
Mitochondrial recessive ataxia syndrome is one of the ataxia neuropathy spectrum disorders also caused by specific mutations in POLG. 11 This group of disorders is characterised by ataxia and neuropathy, variably associated with an encephalopathy with seizures.
Mitochondrial encephalomyopathy, lactic acidosis and strokelike episodes (MELAS)
MELAS syndrome is the combination of mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes, with the majority of cases being caused by a common mtDNA mutation (m.3243A>G) in the mtDNA gene encoding a mitochondrial leucine transfer RNA (tRNA). 12 Stroke-like episodes are typically heralded by migraine headache, vomiting and seizures. Other clinical features include cognitive decline, ataxia, deafness, optic atrophy, short stature, diabetes and hypertrophic cardiomyopathy. The vast majority of individuals with the m.3243A>G mutation never develop strokes and have other clinical problems, most commonly maternally inherited diabetes and deafness. 13 
Myoclonic epilepsy with ragged red fibers (MERRF)
MERRF describes the phenotype of myoclonic epilepsy and ragged red fibres, the latter being a histopathological description of the appearances on muscle biopsy. MERRF is often caused by a mutation in the mtDNA gene encoding the tRNA for lysine, and is one of the disorders specifically associated with epilepsy phenotypes, often with ataxia.
14 Some patients have additional visual, audiological and cardiac involvement.
Pearson syndrome
Pearson syndrome is composed of infantile onset sideroblastic anaemia (often transfusion dependent), lactic acidosis and variable pancreatic exocrine dysfunction. 15 It is associated with a sporadic large deletion in the mtDNA. Many infants do not survive and succumb to liver failure or overwhelming acidosis in the first few years of life, but those who do live beyond infancy inevitably develop features of the Kearns-Sayre syndrome (KSS). 16 
Kearns-Sayre syndrome (KSS)
KSS, also caused by a large mtDNA deletion, may follow Pearson syndrome or present later without preceding anaemia, with onset before 20 years of age with ptosis, progressive external ophthalmoplegia (PEO) and pigmentary retinopathy. 17 Cardiac conduction defects, cerebellar ataxia and cerebral folate deficiency are other features. 16 
Progressive External Ophthalmoplegia (PEO)
PEO is a feature of several disorders or can occur in isolation, and is often associated with mtDNA deletions, which may be single (sporadic) or multiple (secondary to autosomal dominant or recessive nuclear gene mutations).
Leber hereditary optic neuropathy (LHON)
LHON occurs due to specific mtDNA mutations giving rise in adolescence or adult life to painless visual loss, usually an isolated phenomenon affecting both eyes sequentially.
Neuropathy, ataxia and retinitis pigmentosa (NARP)
NARP is often due to mutations in the mtDNA gene MT-ATP6 encoding a subunit of ATP synthase. Individuals with high loads review of the same mutations (typically >90%) present with maternally inherited Leigh syndrome.
Mitochondrial neurogastrointestinal encephalopathy (MNGIE)
MNGIE presents with gastrointestinal dysmotility, peripheral neuropathy and eye involvement, and is caused by mutations in the nuclear gene TYMP that encodes thymidine phosphorylase. 18 This results in an mtDNA depletion syndrome. The enzyme deficiency results in abnormal blood and urinary thymidine and deoxyuridine concentrations, and so blood/urine purine/pyrimidine analysis can suggest the diagnosis.
Myopathy, lactic acidosis and sideroblastic anaemia (MLASA) MLASA is a rare autosomal recessive disorder predominantly affecting the skeletal musculature and bone marrow. It is usually caused by a defect of the YARS2 mitochondrial aminoacyl tRNA synthetase or the PUS1 tRNA pseudo-uridinylation enzyme, both of which are involved in mitochondrial translation.
reversible disorders
While most mitochondrial disorders are considered progressive, a small number display a reversible phenotype. Such disorders include infantile reversible myopathy due to the mtDNA mutation m.14674T>C/G in the MT-TE gene encoding the tRNA for glutamate, and reversible infantile liver disease due to mutations in TRMU encoding an enzyme that functions in normal mitochondrial tRNA modification. 20 Prompt recognition of these rare reversible disorders may enable the appropriate continuation of supportive treatment (such as prolonged ventilation) with the anticipation of subsequent recovery.
investigAtion of MitochondriAl diseAse
If a mitochondrial disorder is suspected, investigations aim first to provide additional evidence (clinical, biochemical, radiological) for mitochondrial disease, then second attempt to identify a specific genetic basis for the disease and third to evaluate for multisystem effects and in particular to detect treatable complications. In practice, these three aims are addressed simultaneously.
Multisystem evaluation
Careful clinical evaluation may reveal multisystem dysfunction, and if signs or symptoms become evident specific investigations will be warranted. Table 2 includes examples of investigations that may be indicated in clinical baseline evaluation and ongoing monitoring.
specific metabolic biochemistry Lactate
Lactate may be elevated in blood and cerebrospinal fluid (CSF) in mitochondrial disorders, but normal lactate levels do not exclude the possibility of a mitochondrial disorder. Measurement of lactate preprandially and postprandially can be useful in distinguishing mitochondrial disorders from disorders affecting glycogen metabolism. Lactate is the end product of anaerobic respiration (glycolysis), being reversibly converted from pyruvate by lactate dehydrogenase. Dysfunction of the respiratory chain results in impaired aerobic respiration, while the ratio of NADH to NAD + (reflecting the abnormal mitochondrial redox status) is increased, driving the production of lactate. Measurement of the lactate/pyruvate ratio can help distinguish respiratory chain dysfunction from defects in earlier steps in pyruvate metabolism, notably pyruvate dehydrogenase deficiency. Lactate may be artefactually increased if a blood sample is difficult to obtain. Lactate may be increased secondary to tissue hypoxia of any cause including sepsis or significant hypotension. Neonatal lactic acidosis is common after a hypoxic-ischaemic insult, but would be expected to normalise over a few days. Elevated CSF lactate is also seen in non-mitochondrial brain diseases such as encephalitis; however, an elevated CSF lactate without evidence of an alternative brain insult or recent seizures is suspicious for mitochondrial disease. The same applies to lactate detected non-invasively by magnetic resonance spectroscopy of the brain.
Plasma amino acids
Plasma amino acids may show an elevated alanine concentration, again reflecting chronically increased pyruvate and lactate levels. Proline may also be elevated, while decreased citrulline may be seen in MELAS and NARP syndromes. 21 
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Plasma acylcarnitines
Plasma acylcarnitines may be helpful in differentiating from other causes of lactic acidosis, including long-chain fatty acid oxidation defects and organic acidaemias, and may also identify specific metabolites in disorders of flavin metabolism and disorders causing toxic damage to the respiratory chain, such as ethylmalonic acidaemia and HIBCH and ECHS1 deficiencies. 23 24 Urine organic acids Urine organic acid analysis may reveal elevated lactate and associated metabolites; intermediates of the TCA cycle, and ethylmalonic acid, may be seen as a non-specific indicator of mitochondrial dysfunction. 3-Methylglutaconic aciduria is seen in a range of disorders including Barth syndrome. 25 Methylmalonic aciduria may be seen in SUCLA2 deficiency and related disorders. Measurement of serum blood biotinidase activity detects biotinidase deficiency, which should be ruled out as this is easily treated with biotin supplementation, and is included in routine newborn screening in some countries.
Novel biomarkers
Novel biomarkers that have been reported to be elevated in mitochondrial disease include fibroblast growth factor 21 (FGF21) and growth and differentiation factor 15 (GDF15), but these are neither specific for mitochondrial disease nor are they elevated in all cases. 27 28 neuroimaging MRI is a powerful tool for evaluating brain involvement. Brain imaging may be undertaken during the investigation of a child with developmental issues, seizures or for other reasons and certain features may give rise to the suspicion of mitochondrial disease. The central nervous system features seen in neuroradiological examination of mitochondrial disorders are diverse (figure 2). Typical features of Leigh syndrome include bilateral symmetrical signal abnormality in the basal ganglia (figure 2b) and brain stem. White matter may be diffusely abnormal (leukodystrophy) in a number of mitochondrial disorders including complex I (figure 2a) and complex II deficiency 29 ; there can be non-specific cerebral atrophy; progressive cerebellar atrophy may be seen in mitochondrial disease but is not specific for this. Specific patterns of brain involvement may be associated with specific genotypes, including leukoecenphalopathy with brainstem and spinal cord involvement with elevated lactate (LBSL, associated with DARS2 mutations). 30 Infarcts that do not correspond to an arterial territory are a hallmark of MELAS syndrome ( figure 2c,d) . 12 Structural brain abnormalities may be seen for example in pyruvate dehydrogenase complex (PDH) deficiency.
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Muscle biopsy
Historically, a muscle biopsy (either open surgical or with large bore needle biopsy) for histopathological tests and functional enzyme assays has been an important investigation for suspected mitochondrial diseases, although more recently the advent of more rapid genetic testing with next-generation sequencing has superseded the need for a muscle biopsy in some situations. However, a muscle biopsy may be helpful in differentiating from other causes of myopathy.
Histochemistry
Histochemical findings can be suggestive of mitochondrial disease, including the detection of ragged red fibres on the modified Gomori trichrome stain, or the observation of cytochrome c oxidase-negative fibres. Non-specific findings include excess lipid deposition and mitochondrial ultrastructural changes on electron microscopic examination. Recently, a modified immunohistochemical technique known as quadruple oxidative phosphorylation (OXPHOS) immunofluorescence has been reported to provide more quantitative data about OXPHOS function. 32 Occasionally, cardiac muscle biopsies undertaken to investigate an unexplained cardiomyopathy reveal features suggestive of mitochondrial disease, including giant mitochondria and abnormal mitochondrial ultrastructural appearances.
Respiratory chain enzymology
Spectrophotometric assays of complexes I-IV in a frozen muscle homogenate assess the function of the respiratory chain complexes and can identify either multiple or isolated complex deficiencies. Combined assay of complexes I+III or II+III indirectly assesses muscle coenzyme Q 10 (CoQ 10 ) which shuttles electrons between these two complexes, and muscle CoQ 10 can also be quantified directly. Complex V can be assayed by polarographic analysis of fresh muscle mitochondria or by blue native gel assay of frozen muscle homogenate.
Isolated complex deficiencies (eg, of complex I) are often caused by mutations in a gene encoding either one of the structural subunits of the complex or an associated assembly factor, and identification of a specific isolated complex deficiency can help direct further targeted genetic analysis.
Mitochondrial DNA depletion syndromes are caused by nuclear gene defects affecting genes responsible for the maintenance and replication of the mtDNA, including POLG, TK2, RRM2B and DGUOK (figure 1a). These result in multiple deficiencies of the respiratory chain complexes. Similarly, disorders affecting mitochondrial DNA transcription or translation can result in multiple complex deficiencies. Since complex II is entirely encoded by nuclear genes, it is not primarily affected in disorders of mtDNA (although complex II activity may be decreased secondarily if the muscle is severely compromised).
A skin biopsy may be obtained either as a punch biopsy or at the time of an open muscle biopsy to obtain cultured fibroblasts. These can be used to assess oxidative phosphorylation function, for example, by microscale oxygraphy, or to assay PDH and pyruvate carboxylase activity; PDH can also be assayed in the muscle sample.
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It should be noted that muscle respiratory chain enzymology may be normal in a patient with genetically confirmed mitochondrial disease, for example, where the tissue-specific phenotype does not involve muscle.
Molecular genetics
The constellation of features from the clinical history, examination and results of initial biochemical and radiological investigations can direct analysis to specific candidate genes (eg, screening for specific mtDNA mutations in MELAS, LHON or NARP syndromes, or for POLG mutations in Alpers syndrome). Particular patterns of respiratory chain enzyme complex deficiencies in the muscle biopsy can also suggest groups of genes to be evaluated. The family history can suggest whether a nuclear gene defect (in a consanguineous family with multiple affected individuals on both sides of the pedigree) or a mtDNA defect (matrilineal pattern of inheritance) is more likely.
Nuclear genes can be assessed with DNA extracted from blood. mtDNA mutation load varies from tissue to tissue, with highest levels of mutation heteroplasmy expected in affected tissues, and as a result mtDNA analysis is best performed on DNA extracted from an affected tissue, usually muscle DNA. However, in infants with severe mtDNA-encoded disease, it is expected that the blood heteroplasmy level will be sufficiently high that analysis of blood DNA will detect mtDNA mutations. mtDNA analysis may start with analysis for large-scale deletions or rearrangements, followed by specific common point mutation analysis, and finally full mtDNA sequencing. Individual candidate nuclear genes can be Sanger-sequenced directly. However, the genetic complexity underlying mitochondrial disease, with hundreds of candidate genes, means that this is an inefficient approach and increasingly next-generation sequencing is being review employed to evaluate larger panels of genes or whole exomes or genomes. Furthermore, as we move away from muscle biopsies as the gold standard diagnostic test, novel bioinformatics tools will be needed to help confirm pathogenicity of observed genetic variants. 9 Parental blood DNA samples are required to evaluate nuclear gene mutations identified in the proband; DNA samples from blood and urinary cellular sediments from the mother may be evaluated in the case of mtDNA-encoded disorders to determine maternal levels of mtDNA mutation heteroplasmy. Subsequently, it may be appropriate to undertake cascade family screening. Identification of the mode of inheritance can also help inform discussions about recurrence risk for future children and potential reproductive options. Involvement of clinical genetics teams is important.
MAnAgeMent of MitochondriAl disorders
The management of a child with mitochondrial disease requires the input of many different healthcare professionals (including review metabolic physicians, neurologists, cardiologists, endocrinologists, gastroenterologists, nephrologists, intensivists, ophthalmologists, audiological physicians, community paediatricians, dietitians, nurses, physiotherapists, speech and language therapists and psychologists) collaborating to optimise clinical management, addressing the numerous complications that arise. Ensuring good nutrition, monitoring growth and developmental parameters, providing appropriate support for education and physical mobility needs are all critical aspects of management.
General supportive interventions need to be tailored according to the patient-specific problems that arise, and can span numerous medical specialities (table 3) . Some invasive interventions such as solid organ transplantation may not be considered appropriate in the context of progressive multisystem disease, but may be considered if there is an isolated single-organ failure in limited circumstances.
specific therapies
There is also a growing evidence base for specific therapies for mitochondrial disorders, 33 although the challenges of undertaking rigorous randomised controlled trials in such disparate and rare disorders are reflected in the relatively small number of high-quality trials identified by the Cochrane review process. 34 
Lactic acidosis
Lactic acidaemia if severe can result in acidosis; in such situations, appropriate use of sodium bicarbonate to normalise acid-base status is required. Dichloroacetate stimulates PDH activity by inhibition of PDH kinase and can decrease lactate levels. However, the impact on long-term outcome is not clear, and long-term use may be associated with peripheral nerve toxicity. 34 
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Treatable disorders
There is a small group of readily treated disorders that respond to specific therapies, and these should be identified promptly and treatment initiated in a timely manner. 5 These include use of CoQ 10 supplements for CoQ 10 biosynthesis defects; riboflavin (vitamin B2) in riboflavin-responsive disorders such as ACAD9 or FLAD1 deficiency 36 37 ; biotin in biotinidase deficiency; and combinations of biotin and thiamine in high doses for biotinthiamine-responsive basal ganglia disease. 38 39 Thiamine is given if PDH deficiency is suspected as some defects are thiamine responsive. A deficiency of 5-methyltetrahydrofolate (the major transport form of folic acid) has been reported in several mitochondrial disorders including KSS and is treatable with regular folinic acid. Supplementation with these therapies may be initiated empirically while awaiting final diagnostic investigations.
Arginine in MELAS syndrome
There is growing evidence for the use of arginine therapy in MELAS syndrome for both acute treatment and prevention of stroke-like episodes. 12 Arginine is required for nitric oxide synthesis, and the observation of low arginine and citrulline levels in patients, particularly during acute stroke episodes, supports the hypothesis that vasodysregulation contributes to the aetiology of the stroke-like episodes.
Potentially detrimental drugs
Certain drugs have the potential to be detrimental in the context of a mitochondrial disorder and should be avoided or used with caution. 40 These include sodium valproate (risk of hepatotoxicity, and contraindicated in patients with POLG mutations) and anaesthetic agents such as propofol. 41 
novel therapies under evaluation Antioxidant therapy
Excessive production of reactive oxygen species occurs when the respiratory chain is dysfunctional, and it is thought that consequent oxidative stress may play an important role in the pathophysiology of mitochondrial disorders. 35 Numerous antioxidants have been used in the treatment of mitochondrial diseases. Therapies include CoQ 10 42 and the related compounds idebenone 33 and EPI-743. 43 N-Acetylcysteine is a cysteine donor review and can replenish glutathione, although evidence for therapeutic efficacy is lacking. Vitamin C, E and chemical analogues are also being evaluated.
Stimulating mitochondrial biogenesis
Approaches aimed at increasing mitochondrial biogenesis have been evaluated, using both pharmacological approaches such as bezafibrate (a PPARα activator) or resveratrol (a SIRT1 sirtuin activator) and dietary approaches via the ketogenic diet, which all result in upregulation of mitochondrial gene expression and subsequent mitochondrial biogenesis. 35 Recently, decanoic acid, a C10 fatty acid produced in response to the ketogenic diet, has been found in vitro to stimulate mitochondrial biogenesis, 44 and may have efficacy in primary mitochondrial disease although formal clinical trials are still needed. 45 
Other novel therapies
Other novel therapeutic approaches include targeting the mitochondrial membrane and its complex lipids 46 ; replacing nucleosides in mtDNA depletion disorders that are associated with nucleoside deficiency 47 ; and gene therapy approaches including recoding mtDNA-encoded genes to be expressed in the nuclear genome (allotopic gene expression), 'conventional' viral vector-mediated nuclear-targeted gene therapies; and selective destruction of mutant mtDNA using restriction endonuclease technologies (see ref 5) .
Future reproductive options
While detailed comment is beyond the scope of this review, parents of a child with mitochondrial disease, or who are known carriers of either nuclear or mitochondrial gene mutations, may consider a number of options for future children, including antenatal testing, preimplantation genetic diagnosis 48 or potentially 'mitochondrial donation' technologies 49 although these methods have generated medical ethical debate.
conclusions
Understanding of normal mitochondrial physiology has been furthered through the insights gained from the clinical and laboratory investigation of patients with diverse mitochondrial genetic disorders. Early consideration of the possibility of a mitochondrial disorder followed by careful clinical assessment and biochemical, radiological and genetic investigation can lead to a diagnosis of mitochondrial disease. Diagnosis will then prompt symptomatic, and in some situations, disease-modifying, therapies. Novel therapies in the pipeline aim to further improve the prognosis for children affected by these frequently devastating disorders.
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